Range Cancer Therapeutics ETF (CNCR)
| Assets | $13.98M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 1.03M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +3.01% |
| Volume | 21,619 |
| Open | 13.62 |
| Previous Close | 13.67 |
| Day's Range | 13.09 - 13.62 |
| 52-Week Low | 9.22 |
| 52-Week High | 17.96 |
| Beta | 1.38 |
| Holdings | 77 |
| Inception Date | Oct 13, 2015 |
About CNCR
The Range Cancer Therapeutics ETF (CNCR) is an exchange-traded fund that is based on the Range Oncology Therapeutics index. The fund tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products. CNCR was launched on Oct 13, 2015 and is issued by Range.
Top 10 Holdings
24.29% of assets| Name | Symbol | Weight |
|---|---|---|
| Geron Corporation | GERN | 3.93% |
| Enliven Therapeutics, Inc. | ELVN | 3.15% |
| Summit Therapeutics Inc. | SMMT | 2.57% |
| Nurix Therapeutics, Inc. | NRIX | 2.29% |
| iTeos Therapeutics, Inc. | ITOS | 2.24% |
| Nuvation Bio Inc. | NUVB | 2.15% |
| Merus N.V. | MRUS | 2.09% |
| ImmunityBio, Inc. | IBRX | 2.07% |
| Blueprint Medicines Corporation | BPMC | 1.92% |
| Revolution Medicines, Inc. | RVMD | 1.87% |
News
Last Week in ETFs: 8 New Defined Outcome ETFs Debut
Last week was a busy one for ETFs, with nine new ETFs launching on the first day of the week alone. Calamos, Innovator, AllianzIM, Direxion, Global X and ProShares were among the issuers rolling out n...
EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION
OKLAHOMA CITY , Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC, adviser to the Range Cancer Therapeutics ETF (CNCR) and the Loncar China BioPharma ETF (CHNA) is pleased to announce the co...
Should Investors Follow Private Equity into Life Sciences?
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Biotech ETFs extend January gains
Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-m...
Specialty biotech funds jump on promising coronavirus, funding news
Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...
3 ETFs For More Moderna Bets
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.